1. Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art
- Author
-
Rocco Papalia, Simone Albisinni, Luigi Schips, Michele Marchioni, Anamaria Autran, Roberto M Scarpa, Matteo Ferro, Francesco Esperto, Moises Rodriguez Socarras, and Juan Gómez Rivas
- Subjects
Nephrology ,Oncology ,medicine.medical_specialty ,Urology ,030232 urology & nephrology ,03 medical and health sciences ,Tumor grade ,0302 clinical medicine ,Renal cell carcinoma ,Internal medicine ,microRNA ,medicine ,Biomarkers, Tumor ,Humans ,Liquid biopsy ,Stage (cooking) ,Carcinoma, Renal Cell ,miRNA ,business.industry ,General Medicine ,medicine.disease ,Prognosis ,Kidney Neoplasms ,Settore MED/24 ,Curative treatment ,030220 oncology & carcinogenesis ,State of art ,Neoplasm Recurrence, Local ,business ,Biomarkers ,Kidney Diseases (G Ciancio, Section Editor) - Abstract
Purpose of ReviewWe aim to summarize the current state of art about the possible use of biomarkers for predicting renal cell carcinoma (RCC) recurrence after curative treatment. In addition, we aim to provide a snapshot about the clinical implication of biomarkers use for follow-up planification.Recent FindingsA wide variety of biomarkers have been proposed. RCC biomarkers have been individuated in tumoral tissue, blood, and urine. A variety of molecules, including proteins, DNA, and RNA, warrant a good accuracy for RCC recurrence and progression prediction. Their use in prediction models might warrant a better patients’ risk stratification.SummaryFuture prognostic models will probably include a combination of classical features (tumor grade, stage, etc.) and novel biomarkers. Such models might allow a more accurate treatment and follow-up planification.
- Published
- 2021